ArticleESMO open2018

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours.

Walter Fiedler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.